Product Description: CHD1Li 6.11 is a potent oncogenic CHD1L inhibitor (IC50=3.3 µM for cat-CHD1L recombinant protein). CHD1Li 6.11 is an orally bioavailable antitumor agent, significantly reducing the tumor volume of CRC xenografts generated from isolated quasi mesenchymal cells (M-phenotype), which possess enhanced tumorigenic properties[1].
Applications: Cancer-programmed cell death
Formula: C21H22BrN5OS
References: [1]Prigaro BJ, et al. Design, Synthesis, and Biological Evaluation of the First Inhibitors of Oncogenic CHD1L. J Med Chem. 2022;65(5):3943-3961.
CAS Number: 2716890-91-2
Molecular Weight: 472.40
Compound Purity: 99.54
Research Area: Cancer
Solubility: DMSO : 100 mg/mL (ultrasonic)
Target: DNA/RNA Synthesis